Aktionsplan Neoleukin Therapeutics, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. weitere details| IPO date | 2014-03-07 |
|---|---|
| ISIN | US64049K1043 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.neoleukin.com |
| Цена ао | 15.1 |
| Preisänderung pro Tag: | 0% (15.1) |
|---|---|
| Preisänderung pro Woche: | 0% (15.1) |
| Preisänderung pro Monat: | 0% (15.1) |
| Preisänderung über 3 Monate: | 0% (15.1) |
| Preisänderung über sechs Monate: | 0% (15.1) |
| Preisänderung pro Jahr: | 0% (15.1) |
| Preisänderung über 3 Jahre: | +489.84% (2.56) |
| Preisänderung über 5 Jahre: | +25.42% (12.04) |
| Preisänderung seit Jahresbeginn: | 0% (15.1) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| Baker Brothers Advisors, LLC | 1221414 | 13 |
| Redmile Group, LLC | 582443 | 6.2 |
| Adage Capital Partners GP L.L.C. | 310000 | 3.3 |
| Nantahala Capital Management, LLC | 299999 | 3.19 |
| Bank of America Corporation | 231779 | 2.47 |
| Vanguard Group Inc | 201539 | 2.14 |
| Renaissance Technologies, LLC | 163447 | 1.74 |
| Morgan Stanley | 107671 | 1.15 |
| Bml Capital Management, LLC | 98664 | 1.05 |
| Blackrock Inc. | 96613 | 1.03 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Ms. Donna M. Cochener-Metcalfe J.D. | Gen. Counsel & Sr. VP of Legal | 403.75k | 1975 (50 Jahre) |
| Mr. Sean Michael Smith | Principal Accounting Officer, VP of Fin. & Controller | N/A | 1986 (39 Jahre) |
| Dr. Jonathan G. Drachman M.D. | CEO, Pres, Principal Financial Officer & Director | 1962 (63 Jahr) | |
| Dr. Priti Patel M.D., M.S. | Chief Medical Officer | 1976 (49 Jahre) | |
| Dr. David Baker | Co-founder & Member of Scientific Advisory Board | ||
| Dr. Carl Walkey Ph.D. | Sr. VP of Corp. Devel. | 1985 (40 Jahre) | |
| Mr. Kamran Alam | Sr. Strategic Advisor | 1974 (51 Jahr) | |
| Dr. Bill Arthur | VP & Head of Research | ||
| Mr. Umut Ulge | VP of Clinical Devel. |
Adresse: United States, Seattle. WA, 188 East Blaine Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.neoleukin.com
Webseite: https://www.neoleukin.com
